2019 GU Cancers Symposium: First-Line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported at the 2019 Genitourinary Cancers Symposium and in The New England Journal of Medicine, Rini et al found significant benefits in overall and progression-free survival with the combination...
2019 GU Cancers Symposium: TIVO-3: Tivozanib vs Sorafenib in Refractory Advanced Renal Cell Carcinoma
The TIVO-3 trial was conducted to confirm progression-free survival results from the TIVO-1 trial, which found an improvement...
Benefit of Annual Screening in Women Aged 35–39 With a Family History of Breast Cancer
Annual screening for women aged 35–39 who have a family history of breast cancer may be highly effective in detecting tumors earlier...
DYNAMO: Duvelisib in Refractory Indolent Non-Hodgkin Lymphoma
In the phase II DYNAMO trial reported in the Journal of Clinical Oncology, Flinn et al found a response rate of nearly 50% with duvelisib, an oral dual inhibitor...
Progress With ALK Inhibitors: When Will We Consider ALK-Positive Lung Cancer a ‘Chronic Disease’?
As reported by Solomon et al in The Lancet Oncology and reviewed in this issue of The ASCO Post, results from a global phase II study of the third-generation ALK inhibitor lorlatinib...
Allen Lichter: The Potential of Value-Based Prescribing in Oncology
Karen Reckamp: PACIFIC Trial of Durvalumab in Stage III Unresectable NSCLC
Damien Hansra: Breast Cancer Surgical Terminology Update
Thomas Witzig: Essential Elements of an Effective Clinical Trials System
Fred Hirsch: Progress With ALK Inhibitors
More Top Stories
Breast Cancer Surgical Terminology Should Be Updated to Reflect Modern Medical Practice
BREAST CANCER is a microscopic disease, with most patients presenting with “localized” stage I to III disease, for which they are offered curative-intent surgery often accompanied by radiation therapy, chemotherapy, and hormonal therapy. More accurately, we now know that patients with localized...
2019 GU Cancers Symposium: First-Line Pembrolizumab Plus Axitinib vs Sunitinib in Advanced Renal Cell Carcinoma
As reported at the 2019 Genitourinary Cancers Symposium (Abstract 543) and in The New England Journal of Medicine, Rini et al found significant benefits in overall and progression-free survival with the combination of pembrolizumab plus axitinib vs sunitinib in the first-line treatment of advanced...
Leaders of Harborside Medical Education Recognized by the Alliance for Continuing Education in the Health Professions
THE PRINCIPALS and staff of Harborside, publisher of The ASCO Post, congratulate Harborside Medical Education (HSME) for staff recognition by the Alliance for Continuing Education (CE) in the Health Professions (the Alliance). Two senior staff were honored during the awards ceremony preceding the...
$30 Million Granted to MD Anderson Scientists for Various Research Investigations
THE UNIVERSITY of Texas MD Anderson Cancer Center was awarded $30 million from the Cancer Prevention and Research Institute of Texas to support research, core facilities, recruitment, and prevention efforts. An additional $19.9 million was awarded to a company co-founded by MD Anderson to support...
Benefit of Annual Screening in Women Aged 35–39 With a Family History of Breast Cancer
Annual screening for women aged 35–39 who have a family history of breast cancer may be highly effective in detecting tumors earlier, according to findings published by Evans et al in The Lancet’s online journal EClinicalMedicine. The FH02 trial found that annual mammograms for...
Selected Abstracts From the San Antonio Breast Cancer Symposium
Each year, The ASCO Post asks Jame Abraham, MD, FACP, Director of the Breast Oncology Program at Taussig Cancer Institute and Professor of Medicine at the Cleveland Clinic Lerner College of Medicine, to offer his picks for the most important research presented at the 2018 San Antonio Breast...
Cutaneous T-Cell Lymphoma: Can Genetic Polymorphisms Help Select Patients for Treatment With Bexarotene?
Bexarotene is a retinoid approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have not responded to at least one previous treatment regimen. Hypertrigylceridemia is the most frequent adverse event related to treatment with bexarotene in CTCL. Even with prophylactic...
Jonathan W. Friedberg, MD, on Follicular Lymphoma: Novel Combination Therapies
Toni K. Choueiri, MD, on Renal Cell Carcinoma: Trial Results on Avelumab Plus Axitinib vs Sunitinib
Ignacio Duran, MD, PhD, on Renal Cell Carcinoma: Results From the METEOR Trial on Cabozantinib vs Everolimus
Zaida Morante, MD, on Triple-Negative Breast Cancer: Delaying Adjuvant Chemotherapy
